• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Bristol-Myers Squibb (BMS) (Group)

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. *

 

	Start	1989-10-04 merged
	Predecessor	Bristol-Myers (Group)
	Industry	pharmaceutical
	Region	New York, NY
	Country	United States (USA)
	Street	430 East 29th Street 14th Floor
	City	10016 New York, NY
	Tel	+1-212-546-4000
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2018-12-31)
	Currency	USD
	Annual sales	22,561,000,000 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	4,947,000,000 (2018-12-31)
	Cash	6,911,000,000 (2018-12-31)
		* Document for �About Section�:
		Record changed: 2022-03-11

Advertisement

More documents for Bristol-Myers Squibb (BMS) (Group)

• [1] Bristol-Myers Squibb Company. (6/3/22). "Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company". New York, NY & San Diego, CA....
• [2] Immatics N.V.. (6/2/22). "Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs". Tübingen, Houston, TX & New York, NY....
• [3] Evotec SE. (5/10/22). "Press Release: Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation". Hamburg....
• [4] Temedica GmbH. (3/15/22). "Press Release: Temedica Announces Cooperation with Bristol Myers Squibb for the Development of a Digital Companion for Psoriasis Patients". Munich....
• [5] Immatics N.V.. (12/14/21). "Press Release: Immatics and Bristol Myers Squibb Enter into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401". Tübingen, Houston, TX & New York, NY....
• [6] Evotec SE. (10/8/21). "Press Release: Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type". Hamburg....
• [7] Cardior Pharmaceuticals GmbH. (8/25/21). "Press Release: Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease". Hanover....
• [8] Bristol-Myers Squibb Company. (8/19/21). "Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma". Princeton, NJ....
• [9] Exscientia Ltd.. (8/18/21). "Press Release: Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate". Oxford....
• [10] Be Biopharma, Inc.. (8/11/21). "Press Release: Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.